Antibodies

11 May 2017 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression
10 May 2017 Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma
10 May 2017 European Commission Approves the Only Immunotherapy for High-risk Neuroblastoma, Bringing Hope to Thousands of Children Affected by a Rare and Devastating Form of Cancer
10 May 2017 Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) In People With Previously Treated Advanced Bladder Cancer
10 May 2017 AstraZeneca provides update on STRATOS 1 Phase III trial of tralokinumab in severe, uncontrolled asthma
09 May 2017 OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer
09 May 2017 FDA Grants Second Approval for BAVENCIO® (avelumab)
09 May 2017 FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer
09 May 2017 OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results
08 May 2017 Crown Bioscience Announces Collaboration to Develop Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Antibody
08 May 2017 Tau Immunotherapy Shows Great Potential in Pre-Clinical Studies
07 May 2017 Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes
05 May 2017 Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria
05 May 2017 European Commission Approves KEYTRUDA® (pembrolizumab) for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who are Transplant-Ineligible and Have Failed BV
05 May 2017 Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ADC-1013 and ATOR-1015
04 May 2017 Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis
04 May 2017 Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
03 May 2017 Stainwei Granted US Patent for anti-VEGF Monoclonal Antibody and its anti-PD-1 mAb demonstrating prolonged anti-tumor activity in pre-clinical studies
02 May 2017 Teneobio’s Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine Release
02 May 2017 TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
02 May 2017 Ablynx completes patient recruitment in its phase III HERCULES study of caplacizumab for the treatment of aTTP
02 May 2017 AstraZeneca’s Imfinzi (durvalumab) receives US FDA accelerated approval for previously treated patients with advanced bladder cancer
29 Apr 2017 Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting
29 Apr 2017 European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Squamous Cell Cancer of the Head and Neck in Adults Progressing On or After Platinum-based Therapy
28 Apr 2017 TG Therapeutics Announces Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the American Academy of Neurology 69th Annual Meeting

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top